Icatibant and ACE inhibitor angioedema
- PMID: 22936825
- PMCID: PMC4543926
- DOI: 10.1136/bcr-2012-006646
Icatibant and ACE inhibitor angioedema
Abstract
Icatibant is a selective bradykinin 2 receptor antagonist, currently licensed for use in hereditary angioedema. Its benefit in ACE inhibitor angioedema is yet to be fully established. A handful of preliminary case reports suggest that it may be of benefit in reducing both symptom severity and possible hospital or intensive care admission. To date, there are no case reports of the usage of Icatibant in the emergency department in the UK. Here we report our experience of Icatibant in a 62-year-old gentleman presenting with severe oral, pharyngeal and laryngeal oedema while on an ACE inhibitor.
References
-
- Burr J. Efficacy of icatibant as treatment for ACE inhibitor-induced angioedema in adults: a systematic review 2011. School of physician assistant studies. Paper 235.
-
- Banerjit A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin converting enzyme inhibitor–induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008;100:327–32. - PubMed
-
- Deeks E. Icatibant. Drugs 2010;70:73–81. - PubMed
-
- Wemze H. ACE inhibitor-induced angioedema: remarkable new perspectives for intensive care/emergency medicine. Anasthesiol Intensivmed Notfallmed Schmerzther 1998;33:637–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous